Adma Biologics Return on Equity

Adma Biologics (ADMA) currently reports a ROE of 41.39%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore Adma Biologics's ROE history and peer comparisons.

Adma Biologics's ROE of 41.39% is higher than the Healthcare sector average of 11.15%. That is roughly 271.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Adma Biologics's current 41.39% should be judged against Healthcare norms (sector average: 11.15%) and against ADMA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 41.39%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Adma Biologics, and consider following ADMA for alerts when major investors trade the stock.

Adma Biologics is classified in the Healthcare sector. On ROE, it currently shows 41.39% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ADMA with unrelated industries.